Pathological heterogeneity of clinically diagnosed corticobasal degeneration
Introduction
In the late 1960s, Rebeiz et al. described a disorder which they called “corticodentatonigral degeneration with neuronal achromasia” [1], [2] Subsequent authors have designated this condition as “corticobasal degeneration” (CBD) or “corticobasal ganglionic degeneration,” (CBGD) [3], [4], [5], [6]. The “classical” clinical picture is of a chronic progressive akinetic–rigid syndrome with asymmetric onset in middle to late life, accompanied by higher cortical dysfunction in the form of an apraxic limb, sometimes displaying an alien limb syndrome, and cortical sensory dysfunction. Movement disorders such as dystonia and myoclonus (action-induced, stimulus-sensitive) may also occur. Supranuclear gaze palsy, dysarthria, ataxia, chorea, blepharospasm, and corticospinal tract signs have also been described [1], [2], [3], [4], [5], [6], [7], [8]. Neuropsychological studies have shown deficits of sustained attention and verbal fluency, as in Alzheimer's disease (AD), along with deficits of praxis, finger tapping, and motor programming, unlike AD. These changes were thought to reflect basal ganglia and posterior frontal lobe involvement in CBD [9], [10]. Although the first reports [1], [2] and early reviews [6], [7], [8] of CBD suggested that dementia was an unusual and late feature, more recent studies with less bias suggest that dementia may be common [11], and indeed may be the first [12], [13] and most frequent presenting feature [14]. Cases presenting with features of frontotemporal dementia (FTD) without a motor disorder have also been reported [11], [15], [16], [17], as have patients with parieto-occipital (Balint-like) cortical dysfunction [18] and a combination of dementia, parkinsonism, and motor neurone disease [19].
Typical pathological findings in CBD comprise cortical atrophy, especially in the frontal and anterior parietal lobes, with degeneration of the substantia nigra. Nerve cell loss and gliosis is seen in the cortex, underlying white matter, thalamus, lentiform nucleus, subthalamic nucleus, red nucleus, midbrain tegmentum, substantia nigra, and locus ceruleus. Many residual nerve cells are swollen and chromatolysed with eccentric nuclei (achromasia [1], [2]), resembling the central chromatolysis of axonal reaction [3], [4], [5], [6]. Neuronal inclusions resembling the globose neurofibrillary tangles (NFTs) of progressive supranuclear palsy (PSP) are present in the substantia nigra, but no cortical NFTs, Pick bodies or Pick cells, senile plaques, Lewy bodies, granulovacuolar change or amyloid deposits are seen; hence, the pathological picture is distinctive [3], [4], [5], [6]. The condition is of unknown aetiology; most cases are sporadic, but occasional familial cases have been reported [13]. No effective treatment is currently known, the syndrome being unresponsive to levodopa.
Hence, CBD is a clinicopathological entity of variable clinical phenotype, for which clinical diagnostic criteria have been suggested [6]. The best predictors for the antemortem clinical diagnosis of CBD are reported to be limb dystonia, asymmetric parkinsonism at onset, and ideomotor apraxia which becomes more severe throughout the illness [20]. Clinical and pathological overlap of CBD with PSP is recognised in some cases [21], [22], [23], and the two conditions may share a common genetic background [24]. Occasional cases with the typical clinical phenotype of CBD but lacking the typical neuropathological features have been reported. We present two further cases which fall into this category and consider their nosological position in the light of a review of the literature describing similar cases.
Section snippets
Case 1
A 60-year-old right-handed man noted progressive difficulty using his left arm, when doing up buttons, shoe laces, or his tie. The left hand developed a tendency to grasp things involuntarily; the left arm became stiff, jerky, and useless. When walking, the left leg tended to drag, and eventually he used a wheelchair. The family noted slowing of speed of thought. At age 64, he had difficulty recognizing friends and relatives. Language comprehension was apparently impaired, and verbal output was
Techniques
Multiple sections representative of a wide variety of cerebral cortical sites, subcortical nuclei, brainstem structures, and cerebellum were taken for histochemical (H and E, Luxol fast blue) and immunohistochemical staining, for which antibodies directed against tau, ubiquitin, β-amyloid (all Dako), α-synuclein (Novo-castra), and αβ-crystallin (Serotec) were used. The extent of sampling in both cases permitted compliance with the Office of Rare Diseases neuropathologic criteria for
Discussion
A clinical diagnosis of CBD was made in both these patients, and both fulfilled suggested clinical diagnostic criteria for CBD [6], but the distinctive neuropathological features of CBD were not seen. The final pathological diagnoses, Alzheimer's disease and Pick's disease, had not been predicted antemortem. The peri-Rolandic motor cortex involvement found in both cases is uncommon and may have contributed to the CBD-like clinical presentation.
A number of previous cases of clinically diagnosed
References (62)
- et al.
Familial dementia with swollen achromatic neurons and corticobasal inclusion bodies: a clinical and pathological study
J. Neurol. Sci.
(1996) - et al.
Alzheimer's disease with asymmetric parietal lobe atrophy: a case report
J. Neurol. Sci.
(1998) The nosology of Hallervorden–Spatz disease
J. Neurol. Sci.
(1995)- et al.
Tau protein pathology in neurodegenerative diseases
Trends Neurosci.
(1998) - et al.
Corticodentatonigral degeneration with neuronal achromasia: a progressive disorder of late adult life
Trans. Am. Neurol. Ass.
(1967) - et al.
Corticodentatonigral degeneration with neuronal achromasia
Arch. Neurol.
(1968) - et al.
Corticobasal degeneration
Brain
(1989) - et al.
Cortical–basal ganglionic degeneration
Neurology
(1990) - et al.
Corticobasal degeneration: a clinical study of 36 cases
Brain
(1994) - et al.
Cortical–basal ganglionic degeneration
Corticobasal degeneration
Corticobasal ganglionic degeneration
The neuropsychological pattern of corticobasal degeneration: comparison with progressive supranuclear palsy and Alzheimer's disease
Neurology
Neuropsychological functioning in cortical–basal ganglionic degeneration: differentiation from Alzheimer's disease
Neurology
Cognitive changes in corticobasal degeneration
Unusual clinical presentations of cortical–basal ganglionic degeneration
Ann. Neurol.
Dementia as the most common presentation of cortical–basal ganglionic degeneration
Neurology
Corticobasal degeneration manifesting as a frontal lobe dementia
Ann. Neurol.
Clinical and pathological overlap in Pick complex
Corticobasal ganglionic degeneration and/or frontotemporal dementia? A report of two overlap cases and review of literature
J. Neurol. Neurosurg. Psychiatry
Pathologically-proven corticobasal degeneration presenting with prominent parieto-occipital cortical dysfunction
Neurobiol. Aging
Familial dementia/parkinsonism/motor neuron disease with corticobasal degeneration pathology but absence of a tau mutation
Neurobiol. Aging
Accuracy of the clinical diagnosis of corticobasal degeneration: a clinicopathological study
Neurology
Neuropathologic overlap of progressive supranuclear palsy, Pick's disease and corticobasal degeneration
J. Neuropathol. Exp. Neurol.
Corticobasal degeneration: neuropathologic and clinical heterogeneity
Neurology
Movement disorders
Corticobasal degeneration shares a common genetic background with progressive supranuclear palsy
Ann. Neurol.
Office of rare diseases neuropathologic criteria for corticobasal degeneration
J. Neuropathol. Exp. Neurol.
The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease
Neurology
Consensus recommendations for the post-mortem diagnosis of Alzheimer's disease
Neurobiol Aging
Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop
Neurology
Cited by (70)
Distinct Heterocyclic Moieties Govern the Selectivity of Thiophene-Vinylene-Based Ligands towards Aβ or Tau Pathology in Alzheimer's Disease
2023, European Journal of Organic ChemistryClinicopathologic subtype of Alzheimer's disease presenting as corticobasal syndrome
2019, Alzheimer's and DementiaCorticobasal degeneration
2019, International Review of Neurobiology“Atypical” atypical parkinsonism: Critical appraisal of a cohort
2017, Parkinsonism and Related DisordersCorticobasal Degeneration and Dementia
2015, Diet and Nutrition in Dementia and Cognitive Decline[<sup>18</sup>F]-FDopa positron emission tomography imaging in corticobasal syndrome
2023, Brain Imaging and Behavior